| Identification | Back Directory | [Name]
L-Lysyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-asparaginyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl-L-alanine | [CAS]
474713-20-7 | [Synonyms]
MK2-IN-5
L-Lysyl-L-lysyl-L-lysyl-L-alanyl-L-leucyl-L-asparaginyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl-L-alanine | [Molecular Formula]
C61H113N21O16 | [MOL File]
474713-20-7.mol | [Molecular Weight]
1396.68 |
| Chemical Properties | Back Directory | [density ]
1.40±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [pka]
3.43±0.10(Predicted) | [Sequence]
Lys-Lys-Lys-Ala-Leu-Asn-Arg-Gln-Leu-Gly-Val-Ala-Ala |
| Hazard Information | Back Directory | [Uses]
MK2-IN-5 is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 targets the protein interaction domain in the MAPK pathway. MK2-IN-5 inhibits HSP25 and HSP27 phosphorylation[1][2][3]. | [in vivo]
MK2-IN-5 (2 mg/kg Intraperitoneal injection, single dose) decreased HSP25 phosphorylation in ventilator-associated lung injury model[2]. | Animal Model: | ventilator-associated lung injury model[2] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Decreased HSP25 phosphorylation. |
| [IC 50]
ERK1; ERK2 | [References]
[1] Gaestel M, et al. Peptides as signaling inhibitors for mammalian MAP kinase cascades [J]. Current pharmaceutical design, 2009, 15(21): 2471-2480. DOI:10.2174/138161209788682299
[2] Damarla M, et al. Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury [J]. PloS one, 2009, 4(2): e4600. DOI:10.1371/journal.pone.0004600
[3] Lopes L B, et al. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor [J]. Biochemical and biophysical research communications, 2009, 382(3): 535-539. DOI:10.1016/j.bbrc.2009.03.056 |
|
| Company Name: |
Fuan Bio
|
| Tel: |
15002819872 |
| Website: |
fuanbio.com |
|